Commentary|Videos|November 26, 2024

Complexities with Managing the Overabundance of Clinical Technology

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses how sites are being burdened by increasingly complex technologies.

In a recent video interview with Applied Clinical Trials, Jeff Sidell, PhD, chief technology officer, Advarra, discussed current challenges in clinical research technology. He highlighted the overabundance of systems and emphasized the need for integration to streamline processes and reduce administrative overhead. Sidell also discussed the potential of AI, particularly predictive analytics, to automate repetitive tasks, enhancing efficiency and quality.

A transcript of Sidell’s conversation with ACT can be found below.

ACT: What are some current trends and challenges you’re seeing right now with technology in clinical research?

Sidell: I think for the most part, it's an overabundance of technology. If you ask somebody who's working in a clinical trial at a site, how many systems they have to touch during the conduct of a clinical trial, it keeps rising over the years. I think it's now up to 20 or so. I mean, 20 separate systems that they've got to go and log into, enter data, or move data from one place to another. Not only are the systems becoming more complicated, the trials themselves are becoming more complicated, so they're going on for longer, the conduct of the trial is much more complex, so you put those two things together, and they're drowning in activities, none of which are actually administering care to a subject. It's all just overhead.


Related to this article

What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
Recruitment in the Age of AI: Q&A with John Worden, Javara
In this Q&A, John Worden, chief commercial officer at Javara, discusses why clinical trial recruitment has remained stubbornly one-size-fits-all, how AI can identify patients at scale without displacing the clinician relationships that drive trust, and what care-integrated research engagement needs to look like for health systems, sponsors, and sites.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.